Gut microbiome effects on cardiometabolic disease through metabolism-modifying metabolites (Gut-MMM)

Evidence indicates that the bacterial flora in the human gastrointestinal tract substantially influences metabolism and development of cardiometabolic diseases. Nevertheless, the extent to which these factors are linked and whether pharmaceuticals can be developed on this basis are currently unclear. The underlying hypothesis of the project is that microbially synthesized molecules do not simply play a role as the body’s energy metabolizers and building blocks; they also play an important role as signal molecules that interact with receptors in endocrine organs.

Participants

Jens B Nielsen (contact)

Professor at Biology and Biological Engineering, Systems and Synthetic Biology

Collaborations

University of Amsterdam

Amsterdam, Netherlands

University of Copenhagen

Copenhagen, Denmark

Funding

Novo Nordisk Fonden

Funding years 2016–2022

Related Areas of Advance and Infrastructure

Life Science Engineering

Area of Advance

Sustainable Development

Chalmers Driving Force

More information

Latest update

2017-02-06